<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320560">
  <stage>Registered</stage>
  <submitdate>10/05/2010</submitdate>
  <approvaldate>26/05/2010</approvaldate>
  <actrnumber>ACTRN12610000420044</actrnumber>
  <trial_identification>
    <studytitle>Effects of B-cell depletion on clinical outcomes and histopathology of renal transplantation</studytitle>
    <scientifictitle>The effect of B-cell depletion versus no induction therapy on clinical outcomes and histopathology in renal transplant recipients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CRG120700129(Cochrane Renal Group)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>renal transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>B cell depletion by intravenous infusion of 500mg of rituximab in saline over one hour once only before reperfusion.
The intervention group also receives immunosuppressive therapy including tacrolimus, mycophenolate mofetil and corticosteroids.</interventions>
    <comparator>control arm receives exactly the same immunosuppressive regimen (tacrolimu+mycophenolate mofetil+steroids) except no B cell depletion</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Renal function estimated by Walser's equation (Am J Transplant 2004; 4: 1826-1835)</outcome>
      <timepoint>Monthly from baseline until 2 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Renal pathology assessed according to the BANFF criteria</outcome>
      <timepoint>before reperfusion and 24 months after transplantation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Human Lymphocyte antigen (HLA) antibody assessed by flow panel reactive antibodies</outcome>
      <timepoint>before Transplantation and every 6 months until 2 years after transplantation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of acute rejection assessed by analysis of serum creatinine and renal biopsy confirmation as data linkage to medical records</outcome>
      <timepoint>12 months and 24 months post transplantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>graft failure defined by dialysis therapy for more than 2 weeks or creatinine levels higher than 10 mg/dl and checked by regular outpatient and telephone follow-up</outcome>
      <timepoint>monthly until 24 months post transplantation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient death checked by regular outpatient and telephone follow-up</outcome>
      <timepoint>monthly until 24 months post transplantation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male or female patients at 15-65 years of age undergoing renal transplantation
Patients who have been informed of the potential risks and side effects of the study
Patients who have given written informed consent to participate in the study</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Donor age greater than 65 years
Patients receiving a perfectly matched kidney (6 matches HLA A, B, DR)
Patients who are recipients of multiple solid organ transplants
Patients undergoing second or subsequent transplantation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Taiwan, Province Of China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Digestive Organ Transplantation Foundation</primarysponsorname>
    <primarysponsoraddress>7, Chung-shan South Rd, Taipei 100, Taiwan</primarysponsoraddress>
    <primarysponsorcountry>Taiwan, Province Of China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Digestive Organ Transplantation Foundation</fundingname>
      <fundingaddress>7, Chung-shan South Rd, Taipei 100, Taiwan</fundingaddress>
      <fundingcountry>Taiwan, Province Of China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>National Science Council, Taiwan</sponsorname>
      <sponsoraddress>7, Chung-shan South Rd, Taipei 100, Taiwan</sponsoraddress>
      <sponsorcountry>Taiwan, Province Of China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Can B cell depletion during the early phase of renal transplantation reduce HLA antibody production and lessen chronic allograft rejection?</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ms, Ming-Hui, Lin</name>
      <address>Study Coordinator, Department of Surgery, National Taiwan University Hospital, 7, Chung-Shan South Rd, Taipeim 100, Taiwan</address>
      <phone>+886 2 23123456-65622</phone>
      <fax />
      <email>octn@ntuh.gov.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr, Meng-Kun, Tsai</name>
      <address>Assistant Professor, Department of Surgery, National Taiwan University Hospital, 7, Chung-Shan South Rd, Taipei 100, Taiwan</address>
      <phone>+886 2 23123456-65622</phone>
      <fax />
      <email>mengkuntsai@ntu.edu.tw</email>
      <country>Taiwan, Province Of China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>